SG11201610536XA - Protocols for treatment of major depressive disorder (mdd) - Google Patents
Protocols for treatment of major depressive disorder (mdd)Info
- Publication number
- SG11201610536XA SG11201610536XA SG11201610536XA SG11201610536XA SG11201610536XA SG 11201610536X A SG11201610536X A SG 11201610536XA SG 11201610536X A SG11201610536X A SG 11201610536XA SG 11201610536X A SG11201610536X A SG 11201610536XA SG 11201610536X A SG11201610536X A SG 11201610536XA
- Authority
- SG
- Singapore
- Prior art keywords
- mdd
- protocols
- treatment
- depressive disorder
- major depressive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462012880P | 2014-06-16 | 2014-06-16 | |
| PCT/US2015/035859 WO2015195567A1 (en) | 2014-06-16 | 2015-06-15 | Protocols for treatment of major depressive disorder (mdd) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201610536XA true SG11201610536XA (en) | 2017-01-27 |
Family
ID=54835238
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201610536XA SG11201610536XA (en) | 2014-06-16 | 2015-06-15 | Protocols for treatment of major depressive disorder (mdd) |
| SG10201811203TA SG10201811203TA (en) | 2014-06-16 | 2015-06-15 | Protocols for treatment of major depressive disorder (mdd) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201811203TA SG10201811203TA (en) | 2014-06-16 | 2015-06-15 | Protocols for treatment of major depressive disorder (mdd) |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9572807B2 (en) |
| EP (1) | EP3154545A4 (en) |
| JP (1) | JP6675330B2 (en) |
| KR (1) | KR102475363B1 (en) |
| CN (1) | CN106572996B (en) |
| AU (1) | AU2015277406B2 (en) |
| CA (1) | CA2952452C (en) |
| SG (2) | SG11201610536XA (en) |
| WO (1) | WO2015195567A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3036571C (en) | 2016-09-12 | 2023-10-03 | Neuralstem, Inc. | Amelioration of neural deficits associated with diabetes |
| US10413534B2 (en) | 2017-02-13 | 2019-09-17 | Neuralstem, Inc. | Amelioration of certain deficiencies due to stroke |
| CA3219364A1 (en) | 2021-06-03 | 2022-12-08 | Alto Neuroscience, Inc. | Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agent |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003293409A1 (en) * | 2002-12-09 | 2004-06-30 | Karl K. Johe | Method for discovering neurogenic agents |
| EP2785347A1 (en) | 2011-12-02 | 2014-10-08 | Dainippon Sumitomo Pharma Co., Ltd. | Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder |
-
2015
- 2015-06-15 EP EP15809513.3A patent/EP3154545A4/en active Pending
- 2015-06-15 AU AU2015277406A patent/AU2015277406B2/en active Active
- 2015-06-15 SG SG11201610536XA patent/SG11201610536XA/en unknown
- 2015-06-15 US US14/740,070 patent/US9572807B2/en active Active
- 2015-06-15 KR KR1020177001207A patent/KR102475363B1/en active IP Right Grant
- 2015-06-15 CN CN201580043884.1A patent/CN106572996B/en active Active
- 2015-06-15 SG SG10201811203TA patent/SG10201811203TA/en unknown
- 2015-06-15 WO PCT/US2015/035859 patent/WO2015195567A1/en active Application Filing
- 2015-06-15 CA CA2952452A patent/CA2952452C/en active Active
- 2015-06-15 JP JP2016573079A patent/JP6675330B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3154545A4 (en) | 2017-12-20 |
| JP2017518330A (en) | 2017-07-06 |
| JP6675330B2 (en) | 2020-04-01 |
| US20150359792A1 (en) | 2015-12-17 |
| AU2015277406A1 (en) | 2017-01-12 |
| CA2952452A1 (en) | 2015-12-23 |
| CA2952452C (en) | 2022-07-26 |
| WO2015195567A1 (en) | 2015-12-23 |
| CN106572996B (en) | 2020-04-07 |
| AU2015277406B2 (en) | 2019-09-19 |
| KR20170029509A (en) | 2017-03-15 |
| KR102475363B1 (en) | 2022-12-07 |
| EP3154545A1 (en) | 2017-04-19 |
| CN106572996A (en) | 2017-04-19 |
| US9572807B2 (en) | 2017-02-21 |
| SG10201811203TA (en) | 2019-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259110A (en) | Treatment of osteoarthritis | |
| HK1247823A1 (en) | Treatment of osteoporosis | |
| IL252839A0 (en) | Treatment of pemphigus | |
| HK1225968A1 (en) | Combination therapy for treatment of hbv infections | |
| GB201701673D0 (en) | Methods of well treatment | |
| PT3212233T (en) | Combination therapy for treatment of disease | |
| FI3851537T3 (en) | Treatment of hyperbilirubinemia | |
| IL285077A (en) | Compounds for treatment of cancer | |
| SG10201801562PA (en) | Combination method for treatment of cancer | |
| SG11201609652RA (en) | Treatment of polybacterials infections | |
| HK1258994A1 (en) | Methods for treatment of diseases | |
| GB201410116D0 (en) | Method of treatment | |
| HK1255221A1 (en) | Methods of treatment using cadotril compositions | |
| IL253028B (en) | Method of treatment | |
| GB201416832D0 (en) | Methods of treatment | |
| IL255498A (en) | Treatment of pruritus | |
| SG11201610536XA (en) | Protocols for treatment of major depressive disorder (mdd) | |
| IL231816A (en) | Devices for treating bone fractures | |
| GB201408297D0 (en) | Treatment of cancer | |
| GB201308466D0 (en) | Improved process for treatment of minewater | |
| HK1246679A1 (en) | Treatment of filarial diseases | |
| GB201410407D0 (en) | Treatment of chagas disease | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201417456D0 (en) | Treatment of cancer |